Objectives: In the last 15 years our research activity collected several HRQoL data, through the EQ-5D-3L and other generic or condition-specific questionnaires. The objective was to assess and compare HRQoL among different population subgroups. MethOds: We reviewed all the HRQoL studies conducted by our research group between 1998 and 2012. We identified several conditions to be compared in terms of VAS score and utility index: these were assessed using the Italian social tariffs and then adjusted for age and sex. Results: The archive included QoL data from 7,754 subjects (51.5% male), grouped in 29 different subgroups: type 1 and 2 diabetes mellitus, moderate to severe haemophilia, major depression, atopic dermatitis, severe and chronic hand eczema, psoriatic arthritis, schizophrenia/schizophrenic disorder, β -thalassemia major, gastroesophageal reflux, abdominal aortic aneurysm, systemic sclerosis, chronic hepatitis B, chronic hepatitis C, hepatitis from other causes, cirrhosis, hepatocellular carcinoma, liver transplant, general Italian population aged from 18 to 75 years. Overall, the subjects were aged from 14 to 96 years (mean(+SD)= 55.7(+17.1), median= 57.7). The adjusted EQ-5D-VAS mean+SD ranged from a minimum of 33.9+14.1 in patients with a major depression episode, to a maximum of 82.5+12.9 in patients with atopic dermatitis 8 weeks after flare. The mean+SD VAS was 73.2+11.4 in the general population. The adjusted mean+SD utility index ranged from 0.60+0.17 in psoriatic arthritis before starting treatment with biological agents, to 0.931+0.09 among chronic hepatitis B patients. cOnclusiOns: The many EQ-5D data collected in the last 15 years are merged now in a unique archive that can be used to assess and compare the burden of disease in terms of HRQoL in different subpopulations. This archive is to be considered preliminary and deemed to be integrated with additional data from ongoing or future projects, and perhaps with other analogous archives created in other contexts and Countires.
Objectives:
A key dimension impacting clinical outcomes in health care evaluation is satisfaction (i.e. the level of meeting user's expectations for the service), which impact adherence and persistence. Yet, evidence regarding patient dissatisfaction is scarce. Thus, we asked what the level of dissatisfaction is after a health centre (HC) visit, and which factors impact the dissatisfaction? MethOds: A prospective survey to primary care patients visiting 3 Finnish HCs (Linnainmaa, Omapihlaja, Pirkkala) in Pirkanmaa district during 31.1-11.2.2011 was done. No inclusion/exclusion criteria were used. Comprehensive patient-, clinician-and HC-related data was collected. The patient's satisfaction was measured immediately after the visit in the form of handling problem during a visit (Likert range 0-10). This was inversed to assess the drawback related to the visit (0= full benefit; problem was solved; 10= no benefit; full drawback). An explorative statistical analysis was done including multivariate data mining in order to find the model with the best Akaike information criteria. The model aimed to demonstrate the independent factors impacting the drawback and control heterogeneity. Results: A total of 90.1% of the full sample (n= 647) answered to the drawback question. 40.3% of the patients had problem solved during the visit (i.e. reported 0) and just 6.9% of the patients experienced drawback exceeding 5. The factors increasing the drawback in the stepwise OLS regression model with the +1 ln-transformation for the drawback were longer waiting time, asthma/copd and male sex. The factors decreasing the drawback were patient's higher subjective health status, patient's higher subjective health status in comparison to others of same age/sex, some long-term conditions (rheumatoid disease, allergy, hip/knee joint erosion), clinician's longer experience, clinician in specialising education and certain HC. cOnclusiOns: Some 60% of the patients experienced that their problem was not fully handled. Multiple factors impact the drawback which could be notified in the planning of HC services.
PIH40 measurement of socIetal medIcal care Preferences wItH tHe same cost Per qaly: a dIscrete cHoIce study
Shiroiwa T. 1 , Saito S. 2 , Shimozuma K. 3 , Kodama S. 4 , Noto S. 5 , Fukuda T. 1 1 National Institute of Public Health, Saitama, Japan, 2 Okayama University, Okayama, Japan, 3 Ritsumeikan University, Kusatsu, Japan, 4 Kyoto University, Kyoto, Japan, 5 Niigata University of Health and Welfare, Niigata, Japan Objectives: The principal of QALY is sometimes referred to as "A QALY is a QALY is a QALY", which means all QALYs have the same value, while QALYs may not fully reflect public preferences. If the use of QALYs in decision making proves beneficial but insufficient, what other factors should be taken into consideration simultaneously? MethOds: We conducted a face-to-face survey using a discrete choice method to measure societal medical care preferences. The profiles of assumed patients consisted of the following four factors: (a) age (young or elderly patient); (b) objective of care (treatment or prevention); (c) severity of health state (severe or mild); and (d) past experience of receiving care (yes or no). These Objectives: Of the many routes of drug administration, some are more acceptable to patients than others; for example when a choice is presented, patients will usually prefer an oral over an injectable medication, all else being equal. Patient preference may be expressed in terms of health and non-health-related measures, which include: health technology-related attributes (including ergonomics, ease of use, convenience), behaviour (e.g. needle phobia and patients' perceptions of treatment), and adverse reactions attributable to the route of administration. Preferences may result in process-related (dis)utility, and be revealed as (non)adherence. This review aims to examine ambulatory patients' preferences for subcutaneously administered, self-injectable medications, compared with other routes of administration for the same medicines. MethOds: Ten electronic databases were searched for publications published between 2002 and 2012 using terms pertaining to methods of administration, preferences and adherence. Eligibility for inclusion was determined through reference to specific criteria by two independent reviewers. Results: Of the 1,146 papers screened, 70 met the inclusion criteria. Studies focused mainly on methods of administration for insulin and treatments of paediatric growth disorders and multiple sclerosis. Pen devices were significantly preferred to needle & syringes administration in 11 out of 12 studies -particularly with respect to ergonomics, convenience and portability; however, preferences between autoinjectors and pen devices were less pronounced. Oral administration was preferred to subcutaneous administration in 6 studies (but did not reach statistical significance), as was inhaler therapy (favoured significantly in 3 out of 4 studies). cOnclusiOns: The review identified a number of studies which revealed important differences in patient preference between methods and routes of drug delivery. Further evidence is required to support the notion that preference translates to better adherence.
PIH35 tHe effect of medIcal devIces wItH dose-memory and remInder functIons on PatIents' treatment adHerence, confIdence and dIsease self-manaGement
Hall R. 1 , Harald-Kongsø J. 2 , Humphrey L. 1 , Willgoss T. 1 1 Adelphi Values, Bollington, UK, 2 Novo Nordisk, Søborg, UK Objectives: Adherence to treatment is an important issue in the management of chronic diseases and an indicator of patients' ability to self-manage their condition. Some medical devices have been designed to help support patients' self-management and adherence by including dose-memory and reminder functions. This literature review explored the role and impact of these devices on patients' adherence to treatment, confidence and disease self-management. MethOds: A search of Medline, Embase and PsycInfo was performed to identify articles published in English from 2003-2013, which studied the effect of devices with memory and/or reminder functions on treatment adherence, confidence and self-management. The main attributes of the abstracts selected for inclusion and full-text review, were summarized. Results: The database searches yielded 940 abstracts. Of the 47 meeting the inclusion criteria, 32 were retained. The articles explored the impact of memory and/or reminder devices on treatment adherence, device usability and users' (patients, health care professionals (HCPs) and caregivers) relationship and attitudes towards the devices. Devices with memory and/or reminder functions were found to improve self-reported and electronically-monitored treatment adherence in prophylactic medication use (e.g. contraceptives) and a range of chronic diseases including HIV, diabetes and asthma. Memory functions were considered valuable in disease management by patients and HCPs. Of particular value was that memory and/or reminder functions provided dose-history information, enhanced patients' confidence with, and ability to manage their medication and condition, and helped reduce forgotten or incorrect medication dosing. cOnclusiOns: The incorporation of memory functions alone and in combination with reminder features in medical devices can improve patient's adherence, confidence and self-management. This can lead to improvements in disease control and clinical outcomes, thereby offering clinical and economic value. This review highlights the importance of conducting further qualitative and quantitative research in this area to fully understand the value of these types of devices to patients and HCPs. Objectives: Compliance with medications among elderly patients is particularly important, as the consequences may be quite serious. Results suggest that use of three or more medications may put a considerable burden on elderly patients and may affect their compliance. This analysis profiles elderly patients across 5EU by the number of medications currently used and their compliance related behaviors. Combination products were considered as one prescription medication. MethOds: Results were taken from the 2011 5EU National Health and Wellness Survey, a nationally representative, self-administered survey. Respondents were adults age 18 and over from France, Germany, Italy, Spain and UK. This analysis focuses on adults age > = 65. Physical and mental quality of life was measured using the SF12v2 scale. Activity impairment was measured using the Work Productivity and Activity Impairment scale. Results: Out of the total sample of age > = 65 (n= 10,612), ~37% of elderly adults across 5EU currently use four or more prescription (Rx) medications to treat their conditions, 44% use 1-3 Rx medications, and 18% use no Rx medications. Activity impairment is greater among those using 4+ medications (38.6 vs. 22.7 vs. 16.0). Emergency room visits and hospitalizations are also higher. This group appears to be more proactive in engaging in cost-saving behaviors to alleviate some of the treatment costs in the past 6 months (30% vs 24% vs 15%) (e.g., asking for generic alternatives (19% vs 16% vs 8%), ever changing prescription to another drug (61% vs 51% vs 45%) and switching to a generic version of a prescribed drug (35% vs 27% vs 18%). cOnclusiOns: Considerably higher health care costs and greater activity impairment can be seen among elderly patients using more tive analysis aims to explore how PRO were used in the French affiliate of Roche. MethOds: A total of 89 local studies performed between 2003 and 2013 were evaluated to determine how PROs were collected and evaluated. Results: Forty (45%) out of 89 studies were clinical trials, 44 (49%) were non-interventional studies (NIS) and 5 were expanded access program studies. A total of 33 (37%) studies used at least one PRO; 13 (39%) were clinical trials and 20 (61%) were NIS. There were no PRO in the field of transplantation, 21% of the studies in oncology used PRO, 47% in virology, 60% in anemia and 72% in rheumatology. More than 3600 sites participated in the 33 studies using PRO: 17424 patients were included, 14237 patients (82%) answered at least one PRO and 12314 (86%) of the questionnaires received were considered to be analyzable for statistical analysis (non analyzable PROs were usually due to missing data). The median number of questionnaires per study was 2, (range 1-6). While most studies in virology and anemia used 1 or 2 questionnaires per study, rheumatology studies used at least 3 questionnaires per study. The median study duration was 12 months, (range 1-60). While 84% of PRO were collected at inclusion in the study, 73% of PROs were received after the 6 month visit, 65% at the 12 month visit and less than 50% after 12 months. Seven studies (21%) used PRO as a primary endpoint, and the percentage of patients who answered the questionnaire answered was higher (mean 91%) than when PRO was a secondary endpoint (mean 79%). cOnclusiOns: Careful consideration should be given to number of questionnaires used per study as quality decreases as number of evaluations increases. Objectives: To confirm the factor structure of the Menopause-Specific Quality of Life (MENQOL) questionnaire for a vulvar/vaginal atrophy (VVA) population by applying confirmatory factor analysis (CFA), and to determine whether improvements in health-related quality of life (HRQL) observed in a VVA population with bazedoxifene/conjugated estrogens (BZA/CE) relative to placebo can be deemed clinically relevant. MethOds: In a randomized control trial, postmenopausal women with ≥ 1 bothersome moderate-to-severe VVA symptom received BZA 20 mg/CE 0.45 or 0.625 mg, BZA 20mg or placebo for 12 weeks. HRQL and treatment satisfaction were evaluated using the MENQOL questionnaire and the Menopause Symptoms-Treatment Satisfaction Questionnaire (MS-TSQ), respectively. The structure of the MENQOL questionnaire was evaluated using a CFA. Clinically important differences (CID) for the MENQOL were determined using a regression model to estimate differences in domain and total scores corresponding to one category difference in MS-TSQ items, which were used as anchors. Results: The postulated CFA model fit the MENQOL data (Bentler's Comparative Fit Index > 0.9). Treatment with BZA 20 mg/ CE 0.45 and 0.625 mg compared with placebo was associated with statistically significant improvements in MENQOL vasomotor and sexual functioning domains, and total score (p < 0.001). BZA 20 mg/CE 0.625 mg was also associated with significant improvements in physical functioning (p= 0.019). Change from baseline in MENQOL vasomotor functioning for BZA 20 mg/CE 0.625 mg over placebo was greater than the estimated CID, with BZA 20 mg/CE 0.45 mg approaching CID. Changes in total score for BZA 20 mg/CE 0.625 mg compared with placebo also approacöhed CID. Changes in MENQOL sexual functioning from baseline over placebo, while statistically significant and quite large, were less than the CID estimate. cOnclusiOns: CFA modeling provides strong support for the existing factor structure of the MENQOL questionnaire. Improvements in HRQL seen with BZA/CE approached or exceeded CIDs for VMS functioning and total score. Objectives: Follow up of pelvic floor muscle function after pelvic floor muscle training and using cube pessary, paying special attention to the changes in the strength of pelvic floor muscle and in the ability to relax. MethOds: To determine the degree of the changes in the strength of pelvic floor muscle and in the ability to relax, 35 patients had been contacted before provided with cube pessaries and pelvic floor muscle training. Thirty out of 35 subjects supported our study. Five subjects were excluded due to vaginitis, so finally 30 survey data were processed. Pelvic floor muscle function measurements were performed at the beginning when cube pessaries were given to the subjects and later after a 3-week period of usage. Patients were selected with the help of the non random sample method. Demographic data and gynecological history selection were based on our own general survey questionnaire, while FemiScan surface EMG was used to measure pelvic floor muscle strength and the ability to relax. Statistical analysis involved t-test or Mann-Whitney U-test, significance level was defined at p< 0.05. Results: Although pelvic floor muscle strength showed positive changes, statistically significant changes were not detected in the surveyed group. In the analysis of survey data of the ability to relax pelvic floor muscle statistically significant difference (p= 0,001) could be detected in the average results either at the beginning when cube pessaries were given to the subjects or after a 3-week period of usage. cOnclusiOns: Cube pessary usage and pelvic floor muscle training may have a positive effect on pelvic floor muscle function. factors were orthogonally combined to construct 16 patient profiles. All assumed medical care had the same ICER (cost per QALY). Respondents were randomly assigned to two of the 16 profiles and asked which one of the patients should preferentially receive treatment from a societal point of view, given a limited medical resource. Respondents were stratified by age and sex. Results: A total of 1091 responses were collected from 50 sites across Japan. The most preferred factor was "younger patient (a)", followed by "treatment (b)" and "severe health state (c)", which had the same degree of preference. No statistical significance was found for "no past experience of care (d)". Public preference for medical care for elderly patients increased with increasing age. University-graduated people tended to prioritize care for patients who are younger and in severer conditions. cOnclusiOns: Our survey revealed that public medical care preferences are influenced by factors such as age, even with the same cost per QALY. Based on an economic evaluation, age is an important factor for decision-making that reflects societal preferences.
PIH36 comParIson of elderly adults By numBer of rx medIcatIons used: results from tHe natIonal HealtH and wellness survey across 5eu countrIes

PIH44 confIrmatory factor analysIs and evaluatIon of clInIcally ImPortant dIfferences In menoPause-sPecIfIc qualIty of lIfe assocIated wItH BazedoxIfene/conjuGated estroGens In a vulvar/ vaGInal atroPHy PoPulatIon
PIH45 examInatIon of PelvIc floor muscle functIon after PelvIc floor muscle traInInG and usInG cuBe Pessary
PIH41 PotentIally InaPProPrIate PrescrIBInG (PIP) and Its assocIatIon wItH Instrumental actIvItIes of daIly lIvInG (Iadl) ImPaIrment In older PeoPle
Moriarty F. 1 , Cahir C. 2 , Fahey T. 1 , Bennett K. 3 1 Royal College of Surgeons in Ireland, Dublin, Ireland, 2 Trinity College Dublin, Dublin 8, Ireland, 3 Trinity Centre for Health Sciences, Dublin, Ireland Objectives: Older people are particularly vulnerable to adverse effects of prescribed drugs. PIP can be defined as the use of medicines with an unfavourable risk benefit ratio. There has been little research on the relationship between PIP and humanistic outcomes, such as functional impairment. This study aims to measure the prevalence of PIP in an older Irish population and to investigate its association with IADL impairment. MethOds: A retrospective cohort study of 2,051 community-dwelling participants in The Irish Longitudinal Study on Ageing (TILDA) aged ≥ 65 years with linked medication dispensing history from a national pharmacy claims database was carried out. Exposure to PIP in the 12 months prior to assessing functional impairment was determined using the Screening Tool for Older Persons' Prescriptions (STOPP), the Beers' criteria (2012) and Assessing Care of Vulnerable Elders (ACOVE) indicators relating to inappropriate medications. Logistic regression was used to determine the association between exposure to PIP and presence of any IADL impairment, adjusting for age, gender, socioeconomic status, number of repeat drug classes co-morbidity and medication adherence. Results: The overall prevalence of PIP was 66.89% (n= 1,372). Of these 514 (25.06%) had one instance of PIP, while 858 (41.83%) had two or more. Prevalence was highest using the STOPP criteria (57.29%), compared to prevalences of 37.64% (Beers' criteria) and 23.5% (ACOVE indicators. Participants with ≥ 2 PIP indicators were significantly more likely to have an IADL impairment (adjusted OR= 1.91; 95%CI= 1.15-3.18) compared to no PIP. Similar associations were found for the individual measures of PIP. Age, number of repeat drug classes and co-morbidity were also significantly associated with IADL impairment. cOnclusiOns: PIP in the elderly is highly prevalent and exposure to PIP is independently associated with increased risk of having IADL impairment. This suggests the importance of considering appropriateness when prescribing medicines in order to minimise adverse outcomes.
PIH42 addInG a remInder sHort messaGe servIce (sms) Before and taBlet comPuter durInG clInIc ImProves electronIc PatIent rePorted outcome measures (eProms) collectIon
Roberts N. , Williams D.
Royal Cornwall Hospital, Truro, UK
Objectives: Patient Reported Outcome Measures (PROMs) monitor both symptom progression and treatment effectiveness, and play an increasing role in everyday clinical practice. Electronic PROMs (ePROMs) enable real-time reporting back to the patient and medical team, comparison with similar patient cohorts and long-term cost-effective outcome measurement. Concerns have, however, been expressed about electronic PROMs collection in the elderly. The primary objective of this three-phase pilot study was to measure uptake using a web-based ePROMs platform following the introduction of reminder short messaging service (SMS) before and Tablet Computer during clinic. MethOds: Eighty-seven consecutive new elective orthopaedic patients in a single surgeon's practice were recruited. Group 1 (n= 27) received only a reminder letter, Group 2 (n= 34) also received a reminder SMS message via mobile or home telephone and Group 3 (n= 26) also had access to a Tablet Computer in clinic. Results: Mean age in Group 1 was 55.1 (24-77) years, Group 2 was 60.5 (23-85) years and Group 3 was 54.2 (17-77) years (p> 0.05). Overall 75% patients had Internet access and 33% of Group 1, 50% of Group 2 and 73% of Group 3 recorded an ePROMs score (p= 0.03). In Group 2 and 3 26% of patients did not remember receiving a SMS message that was delivered. cOnclusiOns: Collecting and using PROMs data in everyday clinical practice is challenging. This small pilot study shows that adding a reminder SMS before and access to a Tablet Computer during clinic improves ePROMs collection onto a clinical outcomes webbased system. Further process improvements, such as additional staff training and telephone call reminders, might further improve uptake and a more comprehensive study is planned. PIH43 eIGHty-nIne local rocHe sPonsored frencH studIes Performed In tHe Past 10 years were evaluated to determIne How PatIent rePorted outcomes were used
